The Puerarin improves renal function in STZ-induced diabetic rats by attenuating eNOS expression

References

• Jia W, Xu A, Chen A, Wu J, Ye J. Chronic vascular complications in diabetes. J Diabetes Res. 2013;2013:858746
   PubMedGoogle Scholar
• Wang F, Huang B, Li J, Liu L, Wang N. Renalase might be associated with hypertension and insulin resistance in Type 2 diabetes. Ren Fail. 2014;36(4):552–6
   PubMed Web of Science ®Google Scholar
• Balakumar P, Bishnoi HK, Mahadevan N. Telmisartan in the management of diabetic nephropathy: A contemporary view. Curr Diabetes Rev. 2012;8(3):183–90
   PubMedGoogle Scholar
• Lopes AA. End-stage renal disease due to diabetes in racial/ethnic minorities and disadvantaged populations. Ethn Dis. 2009;19(1 Suppl 1):S1-47–S1-51
   Google Scholar
• Sahay M, Mahankali RK, Ismal K, Vali PS, Sahay RK, Swarnalata G. Renal histology in diabetic nephropathy: A novel perspective. Indian J Nephrol. 2014;24(4):226–231
   PubMedGoogle Scholar
• Dellamea BS, Leitao CB, Friedman R, Canani LH. Nitric oxide system and diabetic nephropathy. Diabetol Metab Syndr. 2014;6(1):17
   PubMedGoogle Scholar
• Cheng H, Wang H, Fan X, Paueksakon P, Harris RC. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int. 2012;82(11):1176–1183
   PubMedGoogle Scholar
• Zeng R, Duan L, Sun L, et al. A meta-analysis on the relationship of eNOS 4b/a polymorphism and diabetic nephropathy susceptibility. Ren Fail. 2014;36(10):1520–1535
   PubMed Web of Science ®Google Scholar
• Morisada N, Nomura M, Nishii H, et al. Complete disruption of all nitric oxide synthase genes causes markedly accelerated renal lesion formation following unilateral ureteral obstruction in mice in vivo. J Pharmacol Sci. 2010;114(4):379–389
   PubMedGoogle Scholar
• Arya A, Yadav HN, Sharma PL. Involvement of vascular endothelial nitric oxide synthase in development of experimental diabetic nephropathy in rats. Mol Cell Biochem. 2011;354(1–2):57–66
   PubMedGoogle Scholar
• Dellamea BS, Pinto LC, Leitao CB, Santos KG, Canani LH. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: A systematic review and meta-analysis. BMC Med Genet. 2014;15:9
   PubMedGoogle Scholar
• Xu L, Zheng N, He Q, Li R, Zhang K, Liang T. Puerarin, isolated from Pueraria lobata (Willd.), protects against hepatotoxicity via specific inhibition of the TGF-beta1/Smad signaling pathway, thereby leading to anti-fibrotic effect. Phytomedicine. 2013;20(13):1172–1179
   PubMed Web of Science ®Google Scholar
• Ma JQ, Ding J, Xiao ZH, Liu CM. Puerarin ameliorates carbon tetrachloride-induced oxidative DNA damage and inflammation in mouse kidney through ERK/Nrf2/ARE pathway. Food Chem Toxicol. 2014;71:264–271
   PubMed Web of Science ®Google Scholar
• She S, Liu W, Li T, Hong Y. Effects of Puerarin in STZ-induced diabetic rats by oxidative stress and the TGF-beta1/Smad2 pathway. Food Funct. 2014;5(5):944–950
   PubMed Web of Science ®Google Scholar
• Zhong Y, Zhang X, Cai X, Wang K, Chen Y, Deng Y. Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats. PLoS One. 2014;9(1):e85690
   PubMed Web of Science ®Google Scholar
• Wang L, Lin S, Li Z, Yang D, Wang Z. Protective effects of Puerarin on experimental chronic lead nephrotoxicity in immature female rats. Hum Exp Toxicol. 2013;32(2):172–185
   PubMedGoogle Scholar
• Wang L, Lin S, Li Z, Yang D, Wang Z. Protective effects of Puerarin on experimental chronic lead nephrotoxicity in immature female rats. Hum Exp Toxicol. 2013;32(2):172–185
   PubMedGoogle Scholar
• Li Q, Xiao Y, Gong H, et al. Effect of Puerarin on the expression of extracellular matrix in rats with streptozotocin-induced diabetic nephropathy. Natl Med J India. 2009;22(1):9–12
   PubMedGoogle Scholar
• Ma JQ, Ding J, Xiao ZH, Liu CM. Puerarin ameliorates carbon tetrachloride-induced oxidative DNA damage and inflammation in mouse kidney through ERK/Nrf2/ARE pathway. Food Chem Toxicol. 2014;71:264–271
   PubMed Web of Science ®Google Scholar
• Advani A, Connelly KA, Advani SL, et al. Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes. Biomed Res Int. 2013;2013:201475
   PubMedGoogle Scholar
• Jayakumari NR, Reghuvaran AC, Rajendran RS, et al. Are nitric oxide- mediated protein modifications of functional significance in diabetic heart? ye's, -NO', wh'y-NO't? Nitric Oxide. 2014;43:35–44
   PubMedGoogle Scholar
• Prabhakar SS. Role of nitric oxide in diabetic nephropathy. Semin Nephrol. 2004;24(4):333–344
   PubMed Web of Science ®Google Scholar
• Okada S, Saito M, Kazuyama E, et al. Effects of N-hexacosanol on nitric oxide synthase system in diabetic rat nephropathy. Mol Cell Biochem. 2008;315(1–2):169–177
   PubMedGoogle Scholar
• Komers R, Anderson S. Glomerular endothelial NOS (eNOS) expression in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant. 2008;23(9):3037; author reply 3037–3038
   PubMedGoogle Scholar
• Liang J, Chen H, Pan W, Xu C. Puerarin inhibits caspase-3 expression in osteoblasts of diabetic rats. Mol Med Rep. 2012;5(6):1419–1422
   PubMedGoogle Scholar
• Wang Y, Li J, Zhuge L, Su D, Yang M, Tao S. Comparison between the efficacies of curcumin and Puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet. Exp Ther Med. 2014;7(3):663–668
   PubMedGoogle Scholar
• Zhu LH, Wang L, Wang D, et al. Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling. Free Radic Biol Med. 2009;48(4):471–482
   PubMedGoogle Scholar
• Zhong Y, Zhang X, Cai X, Wang K, Chen Y, Deng Y. Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats. PLoS One. 2014;9(1):e85690
   PubMed Web of Science ®Google Scholar
• Chen R, Xue J, Xie M. Puerarin prevents isoprenaline-induced myocardial fibrosis in mice by reduction of myocardial TGF-beta1 expression. J Nutr Biochem. 2011;23(9):1080–1085
   PubMedGoogle Scholar
• Wu L, Qiao H, Li Y, Li L. Protective roles of Puerarin and Danshensu on acute ischemic myocardial injury in rats. Phytomedicine. 2007;14(10):652–658
   PubMedGoogle Scholar
• Hou Q, Ao X, Li G, Zhang Y. Puerarin combined with avandia for diabetic nephropathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37(1):73–77
   PubMedGoogle Scholar
• Lu XL, Liu JX, Wu Q, et al. Protective effects of Puerarin against Ass40-induced vascular dysfunction in zebrafish and human endothelial cells. Eur J Pharmacol. 2014;732:76–85
   PubMedGoogle Scholar
• Zhang S, Chen S, Shen Y, et al. Puerarin induces angiogenesis in myocardium of rat with myocardial infarction. Biol Pharm Bull. 2006;29(5):945–950
   PubMedGoogle Scholar